WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 2 fonti

Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug

A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved medicine with a murky financial outlook.

Raccontata dabiopharmadive.comendpoints.news

Confronto fonti

2 prospettive sulla stessa storia
AI · summaries
biopharmadive.comStai leggendo1 mesi fa

Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug

A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved medicine with a murky financial outlook.

originale
endpoints.news1 mesi fa

Pfizer and Arvinas give disappointing breast cancer drug to Rigel

Pfizer and its partner Arvinas are selling rights to their recently approved breast cancer drug to Rigel Pharmaceuticals.

Leggi questa versione → originale

Timeline cronologica

  1. martedì 12 maggio 2026·biopharmadive.com

    Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug

    A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved medicine with a murky financial outlook.

  2. martedì 12 maggio 2026·endpoints.news

    Pfizer and Arvinas give disappointing breast cancer drug to Rigel

    Pfizer and its partner Arvinas are selling rights to their recently approved breast cancer drug to Rigel Pharmaceuticals.